๎
๎ผ
๎
Relay Therapeutics Inc
RLAY8.560USD
-0.090-1.04%
์ข
๊ฐย 12/26, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
1.48B์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Relay Therapeutics Inc ํ์ฌ
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Companyโs initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Companyโs lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kฮฑ), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kฮฑ.
Relay Therapeutics Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ RLAY
ํ์ฌ ์ด๋ฆRelay Therapeutics Inc
์์ฅ์ผJul 16, 2020
CEOPatel (Sanjiv K)
์ง์ ์261
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃJul 16
์ฃผ์60 Hampshire Street
๋์CAMBRIDGE
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ02139
์ ํ16173708837
์น์ฌ์ดํธhttps://relaytx.com/
์ข
๋ชฉ ์ฝ๋ RLAY
์์ฅ์ผJul 16, 2020
CEOPatel (Sanjiv K)
Relay Therapeutics Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
Dr. Sanjiv K. Patel, M.D.
Dr. Sanjiv K. Patel, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Thomas (Tom) Catinazzo
Mr. Thomas (Tom) Catinazzo
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Sekar (Sek) Kathiresan, M.D.
Dr. Sekar (Sek) Kathiresan, M.D.
Independent Director
Independent Director
--
--
Dr. Claire Mazumdar, Ph.D.
Dr. Claire Mazumdar, Ph.D.
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Mark Murcko, Ph.D.
Dr. Mark Murcko, Ph.D.
Independent Director
Independent Director
996.95K
--
Mr. Brian R. Adams, J.D.
Mr. Brian R. Adams, J.D.
Chief Legal Officer, Secretary
Chief Legal Officer, Secretary
178.96K
-10.01%
Mr. Peter (Pete) Rahmer
Mr. Peter (Pete) Rahmer
Chief Corporate Development Officer
Chief Corporate Development Officer
132.75K
-23.39%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Independent Director
Independent Director
25.00K
--
Dr. Donald A. Bergstrom, M.D., Ph.D.
Dr. Donald A. Bergstrom, M.D., Ph.D.
President - Research and Development
President - Research and Development
--
--
Dr. Linda A. Hill, Ph.D.
Dr. Linda A. Hill, Ph.D.
Independent Director
Independent Director
--
--
์์ต ๋ถ์
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2023
FY2022
FY2021
FY2020
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
United States
677.00K
0.00%
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Nov 18
๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Nov 18
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
๊ธฐํ
52.98%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
SB Investment Advisers (UK) Limited
16.10%
Commodore Capital LP
9.81%
Point72 Asset Management, L.P.
8.52%
Casdin Capital, LLC
6.54%
BlackRock Institutional Trust Company, N.A.
6.05%
๊ธฐํ
52.98%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Hedge Fund
36.68%
Investment Advisor
27.26%
Private Equity
16.70%
Investment Advisor/Hedge Fund
13.16%
Research Firm
2.08%
Individual Investor
1.32%
Venture Capital
0.91%
Sovereign Wealth Fund
0.48%
Family Office
0.45%
๊ธฐํ
0.96%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
457
168.31M
97.11%
-38.09M
2025Q2
460
180.78M
105.44%
-7.40M
2025Q1
473
175.15M
102.43%
-21.99M
2024Q4
463
170.97M
101.10%
-14.45M
2024Q3
455
166.81M
103.61%
+17.06M
2024Q2
434
132.20M
98.83%
-25.01M
2024Q1
423
138.51M
105.71%
-7.14M
2023Q4
410
132.38M
103.96%
-10.79M
2023Q3
396
136.20M
110.68%
-5.83M
2023Q2
397
136.32M
112.15%
-5.86M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
SB Investment Advisers (UK) Limited
27.90M
16.19%
--
--
Jun 30, 2025
Commodore Capital LP
13.35M
7.74%
+3.35M
+33.50%
Jun 30, 2025
Point72 Asset Management, L.P.
13.45M
7.8%
+2.62M
+24.19%
Jun 30, 2025
Casdin Capital, LLC
11.40M
6.61%
+2.30M
+25.28%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.63M
6.16%
-159.25K
-1.48%
Jun 30, 2025
The Vanguard Group, Inc.
9.35M
5.42%
-2.73M
-22.57%
Jun 30, 2025
Bellevue Asset Management AG
8.23M
4.77%
+853.58K
+11.57%
Jun 30, 2025
Tang Capital Management, LLC
8.07M
4.68%
--
--
Jun 30, 2025
State Street Investment Management (US)
5.20M
3.02%
+43.60K
+0.85%
Jun 30, 2025
Nextech Invest, Ltd.
3.85M
2.23%
--
--
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Sat, Dec 6
์ด๋ฆ
๋น์จ
Virtus LifeSci Biotech Clinical Trials ETF
1.4%
Tema Oncology ETF
0.98%
ALPS Medical Breakthroughs ETF
0.51%
State Street SPDR S&P Biotech ETF
0.33%
ProShares Ultra Nasdaq Biotechnology
0.17%
Direxion Daily S&P Biotech Bull 3X Shares
0.16%
Avantis US Small Cap Equity ETF
0.14%
Invesco Nasdaq Biotechnology ETF
0.12%
Invesco RAFI US 1500 Small-Mid ETF
0.09%
iShares Biotechnology ETF
0.08%
๋ ๋ณด๊ธฐ
Virtus LifeSci Biotech Clinical Trials ETF
๋น์จ1.4%
Tema Oncology ETF
๋น์จ0.98%
ALPS Medical Breakthroughs ETF
๋น์จ0.51%
State Street SPDR S&P Biotech ETF
๋น์จ0.33%
ProShares Ultra Nasdaq Biotechnology
๋น์จ0.17%
Direxion Daily S&P Biotech Bull 3X Shares
๋น์จ0.16%
Avantis US Small Cap Equity ETF
๋น์จ0.14%
Invesco Nasdaq Biotechnology ETF
๋น์จ0.12%
Invesco RAFI US 1500 Small-Mid ETF
๋น์จ0.09%
iShares Biotechnology ETF
๋น์จ0.08%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Relay Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Relay Therapeutics Inc์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
SB Investment Advisers (UK) Limited๋ 27.90M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 16.19%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Commodore Capital LP๋ 13.35M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 7.74%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Point72 Asset Management, L.P.๋ 13.45M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 7.80%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Casdin Capital, LLC๋ 11.40M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.61%๋ฅผ ์ฐจ์งํฉ๋๋ค.
BlackRock Institutional Trust Company, N.A.๋ 10.63M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.16%๋ฅผ ์ฐจ์งํฉ๋๋ค.
SB Investment Advisers (UK) Limited๋ 27.90M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 16.19%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Commodore Capital LP๋ 13.35M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 7.74%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Point72 Asset Management, L.P.๋ 13.45M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 7.80%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Casdin Capital, LLC๋ 11.40M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.61%๋ฅผ ์ฐจ์งํฉ๋๋ค.
BlackRock Institutional Trust Company, N.A.๋ 10.63M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 6.16%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Relay Therapeutics Inc์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎Relay Therapeutics Inc์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
SB Investment Advisers (UK) Limited
Commodore Capital LP
Point72 Asset Management, L.P.์ ๋๋ค.
SB Investment Advisers (UK) Limited
Commodore Capital LP
Point72 Asset Management, L.P.์ ๋๋ค.
Relay Therapeutics Inc(RLAY)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, Relay Therapeutics Inc์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 457๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 168.31M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 97.11%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น -8.33% ์ฆ๊ฐํ ์์น์
๋๋ค.
Relay Therapeutics Inc์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎FY2025Q2 ๊ธฐ์ค, Relay Therapeutics Inc์ -- ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ --๋ก ์ ์ฒด ๋งค์ถ์ --%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
